R&D Closed and Collaborative: Mergers, acquisitions, and partner... As we head further into H2, a final look back to the summer’s industry mergers and acquisiti
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Summer’s stretch having drawn out a longer return to our round-ups, as the days shorten and we firmly enter autumn, pharmaphorum takes a look back at the industry
R&D Closed and Collaborative: Mergers, acquisitions, and partner... Welcome to a new pharmaphorum round-up.
Market Access A year of major M&A ahead? The previous few years have seen a slowdown in M&A across the industry, as companies take a cautious approach to expansion.
News Chiesi expands rare disease portfolio with Amryt Pharma acqu... Biopharma and healthcare group Chiesi Farmaceutici S.p.A.
News Boost for mRNA as Moderna to acquire OriCiro for $85 million Biotech Moderna, Inc. and OriCiro Genomics K.K.
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
